Articles related to CHRONIC KIDNEY DISEASE (CKD)
Anemia of Chronic Kidney Disease: Will New Agents Deliver on Their Promise?
A newly developed prolyl hydroxylase inhibitor (agents that increase endogenous erythropoietin production) holds the promise of improving outcomes for patients with anemia of chronic kidney disease. Randomized controlled trials have found these drugs to be at least as effective as erythropoiesis-stimulating agents.
Internal Medicine May 10th 2022
FDA Says No to Vadadustat Approval Due to Safety Concerns
The US Food and Drug Administration (FDA) has said “no” to Akebia Therapeutics’ drug application for vadadustat, a therapy to treat anemia due to chronic kidney disease. Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor designed to mimic the physiologic effect of altitude on oxygen availability. The FDA cited safety concerns as the main reason for it rejecting the application.
Family Medicine/General Practice April 12th 2022
Allopurinol Initiation and All-Cause Mortality Among Patients With Gout and Concurrent Chronic Kidney Disease
In contradistinction to recent reports that showed increased risk of death and no clinical benefit with escalation of allopurinol for progressive CKD, this 5-year population-based review found no increased mortality risk in escalating allopurinol dose and achieving target serum urate levels.
Family Medicine/General Practice February 1st 2022